Protein drug stability: A formulation challenge

Nature Reviews Drug Discovery

Volumn 4, Issue 4, 2005, Pages 298-306

  Frokjaer, Sven ^a   Otzen, Daniel E ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOPHILE; BAY 504798; CYCLODEXTRIN; DETERGENT; HUMAN GROWTH HORMONE; INSULIN ASPART; INSULIN DETEMIR; INSULIN LISPRO; LIPID; MACROGOL; NEW DRUG; PEGINTERFERON ALPHA2A; PEGVISOMANT; POLYGLACTIN; POLYMER; POLYPEPTIDE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ACYLATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; DRUG TRANSPORT; FIBER; FREEZE DRYING; HUMAN; HYDROGEL; IMMUNOGENICITY; LYOPHILISATE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN MODIFICATION; PURE RED CELL ANEMIA; REVIEW; SIDE EFFECT; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG STABILITY; HUMANS; MODELS, MOLECULAR; RECOMBINANT PROTEINS;

EID: 18244365849     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1695     Document Type: Review

References (138)

1. Holmer, A. F. Survey: Medicines In Development for HIV/AIDS (Pharmaceutical Research and Manufacturers Association, Washington DC, 2004).
2. IBM Consulting Services. Pharma 2010: The Threshold of Innovation (IBM, 2003).
3. Dobson, C. M. Chemical space and biology. Nature 432, 824-828 (2004).
4. Pavlou, A. K. & Reichert, J. M. Recombinant protein therapeutics - success rates, market trends and values to 2010. Nature Biotechnol. 22, 1513-1519 (2004).
5. Krishnamurthy, R. & Manning, M. C. The stability factor: importance in formulation development. Curr. Pharm. Biotech. 3, 361-371 (2002).
6. Wang, W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185, 129-188 (1999).
7. Hermelin, S., Crommelin, D. J. A., Schellekenes, H. & Jiskoot, W. Structure-immunogenicity relationship of therapeutic proteins. Pharm. Res. 21, 897-903 (2004).
8. Ahern, T. J. & Manning, M. C. (eds) Stability of Protein Pharmaceuticals - Part A: Chemical and Physical Pathways of Protein Degradation Pharmaceutical Biotechnology Series Vol. 2 (Plenum, New York, 1992).
9. Cleland, J. L., Powell, M. F. & Shire, S. J. The development of stable protein formulations: a close look at protein aggregation, deamidation and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10, 307-377 (1993).
10. Alpar, H. O., Somavarapu, S., Atuah, K. N. & Bramwell, V. W. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. 57, 411-430 (2005).
11. Hussain, A., Arnold, J. J., Khan, M. A. & Ashen, F. Absorption enhancers in pulmonary protein delivery. J. Control. Release 94, 15-24 (2004).
12. Brange, J., Owens, D. R., Kang, S. & Vølund, A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 13, 923-954 (1990).
13. Kurtzhals, P. et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 312, 725-731 (1995).
14. Markussen, J. et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39, 281-288 (1996).
15. Knudsen, L. B. et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43, 1664-1669 (2000).
16. Foldvari, M. et al. Palmitoyl derivatives of interferon α: potential for cutaneous delivery. J. Pharm. Sci. 87, 1203-1208 (1998).
17. Wang, J., Shen, D. & Shen, W. C. Preparation, purification, and characterization of a reversible lipidized desmopressin with potential anti-diurectic activity. Pharm. Res. 16, 1674-1679 (1999).
18. Bhadra, D., Bhadra, S., Jain, P. & Jain, N. K. Pegnology: a review of PEG-ylated systems. Pharmazie 57, 5-29 (2002).
19. Matthews, S. J. & McCoy, C. Peginteferon α2a: a review of approved and investigational uses. Clin. Ther. 26, 991-1025 (2004).
20. Lee, H.-J. & Park, T. G. Preparation and characterization of mono-PEGylated epidermal growth factor: evaluation of in vitro biological activity. Pharm. Res. 19, 845-851 (2002).
21. Veronese, F. & Harris, J. M. Introduction and overview of peptide and protein pegylation. Adv. Drug Deliv. Rev. 54, 453-459 (2002).
22. Dailey L. A., Wittmar, M. & Kissel, T. The role of branched polyesters and their modifications in the development of modern drug delivery vehicles. J. Control. Release 101, 137-149 (2005).
23. Kopecek, J. Smart and genetical engineered biomaterials and drug delivery systems. Eur. J. Pharm. Sci. 20, 1-16 (2003).
24. Crommelin, D. J. et al. Nanotechnological approaches for the delivery of macromolecules. J. Control. Release 87, 81-88 (2003).
25. Peppas, N. A., Bures, P., Leobandung, W. & Ichikawa, H. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 50, 27-46 (2000).
26. Packhaeuser, C. B., Schnieders, J., Oster, C. G. & Kissel, T. In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. 58, 445-455 (2004).
27. Metselaar, J. M., Mastrobattista, E. & Storm, G. Liposomes for intravenous drug targeting: design and applications. Mini Rev. Med. Chem. 4, 319-329 (2002).
28. Muller, R., Radtke, M. & Wissing, S. A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 248, 121-128 (2002).
29. Bjerregaard, S. et al. Parenteral water/oil emulsions containing hydrophilic compounds with enhanced in vivo retention: formulation, rheological characterization and study of in vivo fate using whole body gammascintography. Int. J. Pharm. 215, 13-27 (2001).
30. Pedersen, T. B., Sabra, M. C., Frokjaer, S., Mourdsen, O. G. & Jorgensen, K. Association of acylated cationic decapeptides with dipalmitoylphosphatidylserine-dipalmitoylphosphatidylcholine lipid membranes. Chem. Phys. Lipids 113, 83-95 (2001).
31. Jørgensen, K., Davidsen, J. & Mouritsen, O. G. Biophysical mechanisms of phosholipase A2 activation and their use in liposome-based delivery. FEBS Lett. 531, 23-27 (2002).
32. Ross, C. et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann. Neurol. 48, 706-712 (2000).
33. Sorensen, P. S. et al. Clinical importance of neutralising antibodies against interferon-β in patients with relapsing-remitting multiple sclerosis. Lancet 203, 1184-1191 (2003).
34. Casadevall, N. et al. Pure red-cell aplasia and antierythropoitin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469-475 (2002).
35. Casadevall, N. Antibodies against rHuEPO: native and recombinant. Nephro. Dial. Transplant. 17 (Suppl. 5), 42-47 (2002).
36. Hermelin, S., Schellekenes, H., Crommelin, D. J. & Jiskoot, W. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm. Res. 20, 1903-1907 (2003).
37. Jørgensen, L., Van de Weert, M., Vermehren, C., Bjerregaard, S. & Frokjaer, S. Probing structural changes of proteins incorporated into water-in-oil emulsions. J. Pharm. Sci. 93, 1847-1859 (2004).
38. Holm, J. et al. Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses. J. Immunol. 173, 5258-5267 (2004).
39. Wang, W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. (in the press).
40. Fink, A. L. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Folding Des. 3, R9-R29 (1998).
41. Carpenter, J. F., Kendrick, B. S., Chang, B. S., Manning, M. C. & Randolph, T. W. in Methods in Enzymology (ed. Wetzel, R.) 236-255 (Academic, San Diego, 1999).
42. Gidalevitz, D., Zhengoing, H. & Rice, S. A. Protein folding at the air-water interface studied with X-ray reflectivity. Proc. Natl Acad. Sci. USA 96, 2608-2611 (1999).
43. Nichols, M. R., Moss, M., Reed, D. K., Hoh, J. H. & Rosenberry T. L. Rapid assembly of amyloid-β peptide at a liquid /liquid interface produces unstable β-sheet fibers. Biochemistry 44, 165-173 (2005).
44. Kato, A. & Takagi, T. Formation of intermolecular β-sheet structure during heat denaturation of ovalbumin. J. Agric. Food Chem. 36, 1156-1159 (1988).
45. Pedersen, J. S., Christiansen, G. & Otzen, D. E. Modulation of S6 fibrillation by unfolding rates and gatekeeper residues. J. Mol. Biol. 341, 575-588 (2004).
46. Fields, G. & Alonso, D. Theory for the aggregation of proteins and copolymers. J. Phys. Chem. B 96, 3674-3981 (1992).
47. Chi, E. Y., Krishnan, S., Randolph, T. W. & Carpenter, J. F. Physical stability of proteins in aqueous solution: mechanism and driving forces in non-native protein aggregation. Pharm. Res. 20, 1325-1336 (2003).
48. Kendrick, B. S., Carpenter, J. F., Cleland, J. L. & Randolph, T. W. A transient expansion of the native state precedes aggregation of recombinant human interferon-γ. Proc. Natl Acad. Sci. USA 95, 14142-14146 (1998).
49. Treuheit, M. J., Kosky, A. A. & Brems, D. N. Inverse relationship of protein concentration and aggregation. Pharm. Res. 19, 511-516 (2002).
50. Krishnan, S. et al. Aggregation of granulocyte colony stimulating factor under physiological conditions: characterization and thermodynamic inhibition. Biochemistry 41, 6422-6431 (2002).
51. Hevehan, D. & De Bernardez-Clark, E. Oxidative renaturation of lysozyme at high concentrations. Biotechnol. Bioeng. 54, 221-230 (1997).
52. Gass, J. N., Gunn, K. E., Sriburi, R. & Brewer, J. W. Stressed-out B cells? Plasma-cell differentiation and the unfolded protein response. Trends Immunol. 25, 17-24 (2004).
53. Rutkowski, D. T. & Kaufman, R. J. A trip to the ER: coping with stress. Trends Cell Biol. 14, 20-28 (2004).
54. Ellis, R. J. Macromolecular crowding: an important but neglected aspect of the intracellular environment. Curr. Opin. Struct. Biol. 11, 114-119 (2001).
55. Minton, A. P. Influence of excluded volume upon macromolecular structure and associations in 'crowded' media. Curr. Opin. Biotech. 8, 65-69 (1997).
56. London, J., Skizynia, C. & Goldberg, M. E. Renaturation of Escherichia coli tryptophanase after exposure to 8M urea. Evidence for the existence of nucleation centers. Eur. J. Biochem. 47, 409-415 (1974).
57. Chapman, M. R. et al. Role of Eschericia coli curli operons in directing amyloid fiber formation. Science 295, 851-855 (2002).
58. Huff, M. E., Balch, W. E. & Kelly, J. W. Pathological and functional amyloid formation orchestrated by the secretory pathway. Curr. Op. Struct. Biol. 13, 674-682 (2003).
59. Sunde, M. et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273, 729-739 (1997).
60. Dobson, C. M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329-332 (1999).
61. Harper, J. D. & Lansbury, P. T. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385-407 (1997).
62. Cao, Z. & Ferrone, F. A. A 50th order reaction predicted and observed for sickle hemoglobin nucleation. J. Mol. Biol. 256, 219-222 (1996).
63. Patro, S. Y. & Przybyclen, T. M. Simulations of kinetically irreversible protein aggregate structure. Biophys. J. 66, 1274-1289 (1994).
64. Istrail, S., Schwartz, R. & King, J. Lattice simulations of aggregation funnels for protein folding. J. Comput. Biol. 6, 143-162 (1999).
65. Ferrone, F. Analysis of protein aggregation kinetics. Meth. Enzymol. 309, 256-274 (1999).
66. Clark, P. L. Protein folding in the cell: reshaping the folding funnel. Trends Biochem. Sci. 29, 527-534 (2004).
67. Chiti, F. et al. Kinetic partitioning of protein folding and aggregation. Nature Struct. Biol. 9, 137-143 (2002).
68. Kunjithapatham, R. et al. Role for the α-helix in aberrant protein aggregation. Biochemistry 44, 149-156 (2005).
69. Fernandez-Escamilla, A. M., Rousseau, F., Schymkowitz, J. & Serrano, L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and protein. Nature Biotechnol. 22, 1302-1306 (2004).
70. Chiti, F., Stefani, M., Taddei, N., Remponi, G. & Dobson, C. M. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424, 805-808 (2003).
71. DuBay, K. F. et al. Predicting absolute aggregation rates of amyloidogenic polypeptide chains. J. Mol. Biol. 341, 1317-1326 (2004).
72. Fraser, P. E. et al. Conformation and fibrillogenesis of Alzheimer Aβ peptides with selected substitution of charged residues. J. Mol. Biol. 244, 64-73 (1994).
73. Frokjaer, S. et al. Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry 40, 8397-8409 (2001).
74. Otzen, D. E., Kristensen, P. & Oliveberg, M. Designed protein tetramer zipped together with an Alzheimer sequence: a structural clue to amyloid assembly. Proc. Natl Acad. Sci. USA 97, 9907-9912 (2000).
75. Otzen, D. E. & Oliveberg, M. Salt-induced detour through compact regions of the protein folding landscape. Proc. Natl Acad. Sci. USA 96, 11746-11751 (1999).
76. Ferrone, F. Analysis of protein aggregation kinetics. Meth. Enzymol. 309, 256-274 (1999).
77. Hall, D. & Edskes, H. Silent prions lying in wait: a two-hit model of prion/amyloid formation and infection. J. Mol. Biol. 336, 775-786 (2004).
78. Masel, J. & Jansen, V. A. Designing drugs to stop the formation of prion aggregates and other amyloids. Biophys. Chem. 88, 47-59 (2000).
79. Chen, S., Ferrone, F. & Wetzel, R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl Acad. Sci. USA 99, 11884-11889 (2002).
80. Jarrett, J. T., Berger, E. P. & Lansbury P. T. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's Disease. Biochemistry 32, 4693-4697 (1993).
81. Krebs, M. R., Morozova-Roche, L. A., Daniel, K., Robinson, C. V. & Dobson, C. M. Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Sci. 13, 1933-1938 (2004).
82. Wadai, H. et al. Stereospecific amyloid-like fibril formation by a peptide fragment of β2-microglobulin. Biochemistry 44, 157-164 (2004).
83. O'Nuallain, B., Williams, A. D., Westermark, P. & Wetzel, R. Seeding specificity in amyloid growth induced by heterologous fibrils. J. Biol. Chem. 279, 17490-17499 (2004).
84. Petkova, A. T. et al. Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307, 262-265 (2005).
85. Kardos, J., Yamamoto, K., Hasegawa, K., Naiki, H. & Goto, Y. Direct measurement of the thermodynamic parameters of amyloid formation by isothermal titration calorimetry. J. Biol. Chem. 279, 55308-55314 (2004).
86. Perutz, M. F., Finch, J. T., Berriman, J. & Lesk, A. Amyloid fibers are water-filled nanotubes. Proc. Natl Acad. Sci. USA 99, 5591-5595 (2002).
87. Onoue, S. et al. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm. Res. 21, 1274-1283 (2004).
88. Wurth, C., Guimard, N. K. & Hecht, M. H. Mutations that reduce aggregation of the Alzheimer's Aβ42 peptide: an unbiased search for the sequence determinants of Aβ amyloidogenesis. J. Mol. Biol. 319, 1279-1290 (2002).
89. Manning, M. & Colón, W. Structural basis of protein kinetic stability: resistance to sodium dodecyl sulfate suggests a central role for rigidity and a bias toward β-sheet structure. Biochemistry 43, 11248-11254 (2004).
90. Klibanov, A. M. Why are enzymes less active in organic solvents than in water? Trends Biotechnol. 15, 97-101 (1997).
91. Partridge, J., Moore, B. D. & Halling, P. J. α-chymotrypsin stability in aqueous-acetonitrile mixtures: is the native enzyme thermodynamically or kinetically stable under low water conditions? J. Mol. Catal., B Enzym. 6, 11-20 (1999).
92. Machius, M., Declerck, N., Huber, R. & Wiegand, G. Kinetic stabilization of Bacillus licheniformis α-amylase through introduction of hydrophobic residues at the surface. J. Biol. Chem. 278, 11546-11553 (2003).
93. Murphy, C. M. Peptide aggregation in neurodegenerative disease. Annu. Rev. Biomed. Eng. 4, 155-174 (2002).
94. Conway, K. A., Rochet, J.-C., Bieganski, R. M. & Lansbury, P. T. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294, 1346-1349 (2001).
95. Taniguchi, S. et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614-7623 (2005).
96. Tjernberg, L. O. et al. Arrest of β-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 271, 8545-8548 (1996).
97. Rzepecki, P. et al. Prevention of Alzheimer's disease-associated Aβ aggregation by rationally designed nonpeptidic β-sheet ligands. J. Biol. Chem. 279, 47497-47505 (2004).
98. Gestwicki, J. E., Crabtree, G. R. & Graef, I. A. Harnessing chaperones to generate small-molecule inhibitors of amyloid β aggregation. Science 306, 865-869 (2004).
99. Shire, S. J., Shahrokh, Z. & Liu, J. H. Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 93, 1390-1402 (2004).
100. Timasheff, S. Protein hydration, thermodynamic binding, and preferential hydration. Biochemistry 41, 13473-13482 (2002).
101. Baldwin, R. L. How Hofmeister ion interactions affect protein stability. Biophys. J. 71, 2056-2063 (1996).
102. De Bemardez-Clark, E., Schwarz, E. & Rudolph, R. Inhibition of aggregation side reactions during in vitro protein folding. Meth. Enzymol. 309, 217-236 (1999).
103. Golovanov, A. P., Hautbergue, G. M., Wilson, S. A. & Lian, L.-Y. A simple method for improving protein solubility and long-term stability. J. Am. Chem. Soc. 126, 8933-8939 (2004).
104. Webb, S. D., Cleland, J. L., Carpenter, J. F. & Randolph, T. W. A new mechanism for decreasing aggregation of recombinant human interferon-γ by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20. J. Pharm. Sci. 91, 543-558 (2002).
105. Kerwin, B. A., Heller, M. C., Levin, S. H. & Randolph, T. W. Effects of Tween 80 and sucrose on acute short-term stability and long-term storage at -20 °C of a recombinant hemoglobin. J. Pharm. Sci. 87, 1062-1068 (1998).
106. Arakawa, T. & Kita, Y. Protection of bovine serum albumin from aggregation by Tween 80. J. Pharm. Sci. 89, 646-651 (2000).
107. Rozema, D. & Gellman, S. H. Artificial chaperone-assisted refolding of carbonic anhydrase B. J. Biol. Chem. 271, 3478-3487 (1996).
108. Tsai, A. M., van Zanten, J. H. & Betenbaugh, M. J. II: Electrostatic effect in the aggregation of heat-denatured RNase A and implications for protein additive design. Biotechnol. Bioeng. 59, 281-285 (1998).
109. Zhao, H., Tuominen, E. K. J. & Kinnunen, P. K. J. Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. Biochemistry 43, 10302-10307 (2004).
110. Knight, J. D. & Miranker, A. D. Phospholipid catalysis of diabetic amyloid assembly. J. Mol. Biol. 341, 1175-1187 (2004).
111. Necula, M., Chirita, C. N. & Kuret, J. Rapid anionic micelle-mediated α-synuclein fibrillization in vitro. J. Biol. Chem. 278, 46674-46680 (2003).
112. Chirita, C. N. & Kuret, J. Evidence for an intermediate in tau filament formation. Biochemistry 43, 1704-1714 (2004).
113. Frömming, K.-H. & Szejtli, J. Cyclodextrins in Pharmacy (Kluwer Academic, Dordrecht, 1994).
114. Larsen, K. L. Large cyclodextrins. Biol. J. Armenia 53, 9-26 (2001).
115. Banga, A. K. & Mitra, R. Minimization of shaking-induced formation of insoluble aggregates of insulin by cyclodextrins. J. Drug Target. 1, 341-345 (1993).
116. Dotsikas, Y. & Loukas, Y. L. Kinetic degradation study of insulin complexed with methyl-β cyclodextrin. Confirmation of complexation with electrospray mass spectrometry and 1H-NMR. J. Pharm. Biomed. Anal. 29, 487-494 (2002).
117. Tokihiro, K., Irie, T., Uekama, K. & Pitha, J. Potential use of maltosyl-β-cyclodextrin for inhibition of insulin self-association in aqueous solution. Pharm. Sci. 1, 49-53 (1995).
118. Otzen, D. E., Knudsen, B. R., Aachmann, F. L., Larsen, K. L. & Wimmer, R. Structural basis for cyclodextrins' suppression of human growth hormone aggregation. Protein Sci. 11, 1779-1787 (2002).
119. Hagenlocher, M. & Pearlman, R. Use of a substituted cyclodextrin for stabilization of solutions of recombinant human growth hormone. Pharm. Res. 6, S30 (1989).
120. Sharma, L. & Sharma, A. Influence of cyclodextrin ring substituents on folding-related aggregation of bovine carbonic anhydrase. Eur. J. Biochem. 268, 2456-2463 (2001).
121. Sigurjonsdottir, J. F., Loftsson, T. & Masson, M. Influence of cyclodextrins on the stability of the peptide salmon calcitonin in aqueous solution. Int. J. Pharm. 186, 205-213 (1999).
122. Aachmann, F. L., Otzen, D. E., Larsen, K. L. & Wimmer, R. Structural background of cyclodextrin-protein interactions. Protein Eng. 16, 1-8 (2003).
123. Cooper, A. Effect of cyclodextrins on the thermal stability of globular proteins. J. Am. Chem. Soc. 114, 9208-9209 (1992).
124. Otzen, D. E. & Oliveberg, M. A simple way to measure protein refolding rates in water. J. Mol. Biol. 313, 479-483 (2001).
125. Karuppiah, N. & Sharma, A. Cyclodextrins as protein folding aids. Biochem. Biophys. Res. Commun. 211, 60-66 (1995).
126. Easton, C. J. & Lincoln, S. F. Modified Gyclodextrins: Scaffolds and Templates for Supramolecular Chemistry (Imperial College Press, London, 1999).
127. Szejtli, J & Osa, T (eds). Comprehensive Supramolecular Chemistry (Elsevier Science, Oxford, 1996).
128. Franks, F. Protein destabilization at low temperatures. Adv. Protein Chem. 46, 105-139 (1995).
129. Wang, W. Lyophilization and development of slid protein pharmaceuticals. Int. J. Pharm. 203, 1-60 (2000).
130. Franks, F. Freeze-drying of bioproducts: putting principles into practice. Eur. J. Pharm. Biopharm. 45, 221-229 (1998).
131. Franks, F. Long-term stabilization of biologicals. Biotechnology (NY) 12, 253-256 (1994).
132. Levine, H. & Slade, L. Water as a plasticizer: physico-chemical aspects of low-moisture polymeric systems. Water Sci. Rev. 3, 79-185 (1988).
133. Costantino, H. R., Langer, R. & Kibanov, A. M. Moisture-induced aggregation of lyophilized insulin. Pharm. Res. 11, 21-29 (1994).
134. Yoshioka, S., Aso, Y., Izutsu, K. & Terao, T. Aggregates formed during storage of β-galactosidase in solution and in the freeze-dried state. Pharm. Res. 10, 687-691 (1993).
135. Klibanov, A. M. & Schefiliti, J. A. On the relationship between conformation and stability in solid pharmaceutical protein formulations. Bioctechnol. Lett. 26, 1103-1106 (2004).
136. Brange, J., Andersen, L., Laursen, E. D., Meyn, G. & Rasmussen, E. Toward understanding insulin fibrillation. J. Pharm. Sci. 86, 517-525 (1997).
137. Malencik, D. A. & Anderson, S. R. Dityrosine as a product of oxidative stress and fluorescent probe. Amino Acids 25, 233-247 (2003).
138. Dobson, C. M. Protein folding and misfolding. Nature 426, 884-890 (2003).